Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Economic information and modeling report

Modeling overview

19 evidence topics · 15 sources

Summary

  • AD109 has no published price, and no cost-effectiveness or budget impact analysis of AD109 was identified.
  • Company market sizing: the prospectus estimates approximately 80 million people with OSA in the United States aged 30 to 69 years, from a study Apnimed commissioned from Clarivate, and approximately one billion worldwide (WHO). The published Apnimed- and Clarivate-authored estimate (Sönmez et al. 2025) is 83.7 million U.S. adults aged 20 years and older in 2024, with OSA defined as an AHI4 of 5 or more events/hr (52% mild, 30% moderate, 18% severe). The two sources state different age bands. The prospectus also cites approximately 3 million new diagnoses per year (Komodo claims), approximately 23 million unique patients with an OSA diagnosis active in the healthcare system from 2019 to 2024 (IQVIA claims), and approximately 10.5 million diagnosed but untreated people. The last figure comes from an Inspire-supported National Sleep Foundation survey of 1,015 adults with self-reported diagnosis, in which approximately 31% of those diagnosed were not receiving treatment.
  • Company payer research reports that payers perceive PAP non-compliance at greater than 60%; Apnimed's planned health economics and outcomes research may include real-world analyses of adherence, healthcare utilization, functional outcomes, and nocturnal oxygenation.
  • Published cost-effectiveness of OSA treatments: CPAP for moderate to severe OSA had an ICER of $15,915 per QALY gained over a lifetime horizon in a Markov model (Pietzsch et al. 2011), and ICERs of $3354 (third-party payer) and $314 (societal) per QALY gained (Ayas et al. 2006). In another analysis, CPAP cost $12,495 per DALY averted from the health care system perspective and was dominant from the societal perspective (Streatfeild et al. 2019). A meta-analysis of 15 studies (34 in the systematic review) found CPAP cost-effective against other treatments collectively, against no treatment, and against oral appliances, with low certainty (Sajith Kumar et al. 2025). Hypoglossal nerve stimulation increased lifetime costs by $42,953 with an ICER of $39,471/QALY in a 5-state Markov model (Pietzsch et al. 2015). Published obesity models include OSA as a modeled outcome or complication (ICER 2025; Hoog et al. 2025; Annemans et al. 2026).
  • Payer coverage of OSA treatments: Medicare initially limits CPAP coverage to a 12-week period and continues it only for beneficiaries who benefit (NCD 240.4). CMS states that beneficiaries prescribed Zepbound for moderate to severe OSA in adults with obesity should continue to receive Medicare Part D coverage, subject to the plan's utilization management requirements. An Aetna prior authorization policy for tirzepatide in OSA sets an initial authorization of 6 months and a continuation of 12 months, with continuation requiring a positive response. ICER reports that coverage was easier to obtain when a comorbidity was on the FDA label.

Product-specific economic evaluation of AD109

No evidence found.